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Purpose: A recent study revealed that polyethylene (PE) would cause extra carbon-ion attenuation per
range shift by 0.45%/cm due to compositional differences in nuclear interactions. The present study aims to
assess the influence of PE range compensators on tumor dose in carbon-ion radiotherapy.
Methods: Carbon-ion radiation was modeled to be composed of primary carbon ions and secondary particles,
for each of which the dose and the relative biological effectiveness (RBE) were estimated at a tumor depth
in the middle of spread-out Bragg peak. Assuming exponential behavior for attenuation and yield of these
components with depth, the PE effect on dose was calculated for clinical carbon-ion beams and was partly
tested by experiment. The two-component model was integrated into a treatment-planning system and the
PE effect was estimated in two clinical cases.
Results: The attenuation per range shift by PE was 0.1%–0.3%/cm in dose and 0.2%–0.4%/cm in RBE-
weighted dose, depending on energy and range-modulation width. This translates into reduction of RBE-
weighted dose by up to 3% in extreme cases. In the treatment-planning study, however, the effect on RBE-
weighted dose to tumor was typically within 1% reduction.
Conclusions: The extra attenuation of primary carbon ions in PE was partly compensated by increased
secondary particles for tumor dose. In practical situations, the PE range compensators would normally
cause only marginal errors as compared to intrinsic uncertainties in treatment planning, patient setup, beam
delivery, and clinical response.
PACS numbers: 87.53.Bn, 87.55.dk, 87.56.ng
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I. INTRODUCTION
The essence of radiotherapy with carbon-ion beams
is conformation of a spread-out Bragg peak (SOBP),
which is a delivered high-dose region concurrently en-
hanced by relative biological effectiveness (RBE), to a
tumor. In a conventional broad-beam system, a custom-
shaped range compensator shortens extra beam range
in the field to minimize exposure of normal tissue be-
yond the tumor.1 At the National Institute of Radio-
logical Sciences (NIRS), the range compensators have
variable water-equivalent (WE) thickness between 0.3 cm
and 20 cm. For the material, high-density polyethylene
(PE) has been commonly used in carbon-ion radiother-
apy facilities.2–4
a)This study was in part presented at the 106th Scientific Meeting
of the Japan Society of Medical Physics in Suita, Osaka, Japan,
16–18 September 2013 and at the 53rd Scientific Meeting of the
Particle Therapy Co-Operative Group in Shanghai, China, 12–14
June 2014. It has also been fully published in Medical Physics 41(7)
071704, July 2014 (http://dx.doi.org/10.1118/1.4870980).
b)nkanemat@nirs.go.jp
It was revealed recently that range shifting with
PE would cause extra attenuation of carbon ions by
0.45%/cm as compared to water,5 due to non water
equivalence in nuclear interactions originated from com-
positional differences. In dosimetry, dose to water is of-
ten measured in non-water phantom with correction by
fluence correction factor, which is a predetermined ratio
of dose-in-water to dose-to-water in the phantom. The
fluence correction factor varies among beams, materials,
and depths and can be specifically determined by exper-
iment or Monte Carlo simulation.6–13
The non water equivalence in nuclear interactions has
been long ignored in treatment planning, beam delivery,
and clinical studies. It is therefore urgent to assess realis-
tic influence of the PE range compensators on carbon-ion
radiotherapy. The PE effect on dose can be evaluated
in the same manner as for the fluence correction factor,
which would, however, be impractical because clinical
carbon-ion beams are specific to facilities with a wide
variety of energies and range modulations. In addition,
RBE of the carbon-ion beams varies with depth in wa-
ter. These complexities would naturally demand radical
simplification in physical and biological modeling of the
PE effect to enable clinical dose evaluation.
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II. MATERIALS AND METHODS
A. Modeling framework
1. The treatment system
For conventional carbon-ion radiotherapy at NIRS ex-
cept for rare ocular-melanoma cases, carbon ions are ac-
celerated to an energy per nucleon of E/A = 290, 350,
400, or 430 MeV by the Heavy Ion Medical Accelerator in
Chiba (HIMAC). The beam is extracted and transported
to one of three treatment rooms, where it is broadened
three-dimensionally to form a clinical carbon-ion beam as
follows:14 A beam-wobbling system, which is composed of
a pair of electromagnets and a variable scatterer, wobbles
the scattered beam in a circular orbit to form a uniform
field of 10, 15, or 20 cm in diameter.15 One of 13 ex-
changeable ridge filters modulates the beam range to a
designed width between 2 cm and 15 cm in WE length
and forms a SOBP in the depth–dose distribution. A
range shifter finely degrades the energy and shortens the
range from those specific to the four extraction energies.
Scattering variation induced by the range modulation
and shifting necessitates intermittent adjustment of the
wobbling condition with range shift to retain sufficient
field uniformity. For all these combinations, there are
currently about 500 clinical carbon-ion beams in the
treatment-planning system (XiO-N, Mitsubishi Electric
Corporation, Tokyo) registered with associated beam
data including relative doseDw and RBE ǫw as a function
of depth d in water. While the dose data were measured,
the RBE data were originated from ridge-filter design
by Monte Carlo simulation integrated with radiobiology
models to address mixing of carbon ions and a wide spec-
trum of secondary particles.2,16,17
In treatment planning, among the clinical carbon-ion
beams, the one that minimally covers a given tumor tar-
get with its SOBP is selected and conformed to the tar-
get with a collimator and a range compensator.18 The
monitor-unit number is experimentally determined for
each treatment beam to deliver the prescribed dose at
a reference depth in water without the range compen-
sator. As every target tumor should be in the SOBP, the
reference depth is set to the mid-SOBP depth:
dmid = R−
M
2
, (1)
where R is the unmodulated beam range and M is the
range-modulation width. Because depth-dependent anal-
ysis may be beyond this study intended for assessment
of clinical influence, we simply evaluate dose and RBE in
the middle of SOBP: mid-SOBP dose Dmid = Dw(dmid)
and mid-SOBP RBE ǫmid = ǫw(dmid), unless noted oth-
erwise.
2. Nuclear interactions
In conventional analytic modeling of nuclear interac-
tions in proton beams,12,19 the secondary particles were
assumed to deposit dose locally, which may be appropri-
ate for target-nucleus recoil and fragments produced in
nuclear breakup at rest. In carbon-ion beams, the dose
originated from target nuclei is generally trivial in com-
parison to high ionization of carbon ions. Instead, light
nuclei constantly produced in matter by fragmentation
of projectile carbon ions dominate the secondary-particle
dose and penetrate far beyond the carbon ions.20 We as-
sumed that neither the target nuclide nor incident en-
ergy strongly influences how the projectile nucleus may
break up,21 which was experimentally valid for carbon-
ion beams.22 Although about as many neutrons as pro-
tons may be produced via nuclear fragmentation, the
neutrons mostly escape from the field and are only rele-
vant to the stochastic effect.23
3. Two-component model
We model a carbon-ion radiation as a mixture of pri-
mary carbon ions and secondary particles, in which the
mid-SOBP dose is decomposed into respective contribu-
tions:
Dmid = D1 +D2. (2)
In the exponential-attenuation approximation, carbon-
ion dose D1 will decrease with PE range shift s by the
relative carbon-ion attenuation factor:
f1 = e
−κs ≈ 1− κ s, (3)
where κ = 0.45%/cm is the relative carbon-ion attenua-
tion coefficient for PE range shift.5 The secondary parti-
cles will increase inversely with reduction of the primary
carbon ions. In the first-order approximation, secondary-
particle dose D2 will thus increase with PE range shift s
by the relative secondary-particle yield factor:
f2 ≈
1
f1
= eκs ≈ 1 + κ s. (4)
4. Dose modification
We define dose modifying factor fD as the ratio of dose
Dmid,s with PE range shift s to dose Dmid without PE,
which is the inverse of the fluence correction factor for
dosimetry. In the two-component model, it is formulated
as
fD =
Dmid,s
Dmid
=
f1D1 + f2D2
D1 +D2
≈ 1− κD s, (5)
where κD is the dose attenuation coefficient given by
κD =
D1
D2
− 1
D1
D2
+ 1
κ. (6)
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5. RBE modifification
The RBE that has been used for carbon-ion radio-
therapy at NIRS was originally defined for an in vitro
endpoint: survival fraction S = 10% for human salivary
gland (HSG) cells,24 as
ǫ =
2βDγ√
α2 − 4β lnS − α
, (7)
where α and β are the linear and quadratic dose coeffi-
cients of the HSG-cell survival response for the radiation
of interest and Dγ is the reference photon dose for the
same endpoint.
In the lesion-additivity model,25,26 the RBE of the two-
component radiation is given by a dose-weighted average:
ǫmid =
ǫ1D1 + ǫ2D2
D1 +D2
, (8)
where ǫ1 and ǫ2 are the RBEs for the primary carbon
ions and for the secondary particles.
We define RBE modifying factor fǫ as the ratio of the
RBE with PE range shift to that without PE:
fǫ =
(
ǫ1f1D1 + ǫ2f2D2
f1D1 + f2D2
)(
ǫ1D1 + ǫ2D2
D1 +D2
)
−1
. (9)
6. Clinical-dose modification
In carbon-ion radiotherapy at NIRS, clinical doses are
prescribed in RBE-weighted dose with extra scaling typ-
ically by factor 1.44 to accommodate to historical treat-
ment protocols.27 The clinical dose per monitor unit will
vary with PE range shift s by a clinical-dose modifying
factor:
fǫD = fǫ fD =
ǫ1f1D1 + ǫ2f2D2
ǫ1D1 + ǫ2D2
≈ 1− κǫD s, (10)
where κǫD is the clinical-dose attenuation coefficient
given by
κǫD =
ǫ1
ǫ2
D1
D2
− 1
ǫ1
ǫ2
D1
D2
+ 1
κ. (11)
7. Energy dependence
Parameters D1/D2 and ǫ1/ǫ2 are specific to individ-
ual ridge filters. In a group of clinical carbon-ion beams
sharing the same ridge filter, D1/D2 will vary with ex-
traction energy or beam range due to attenuation of the
primary carbon ions and yield of the secondary particles
by nuclear interactions while ǫ1/ǫ2 may be approximately
invariant. Dose D1 may decrease with the primary car-
bon ions that attenuate exponentially with attenuation
length λw = 25.5 cm in water,
5 and D2 may increase just
inversely in the first-order approximation. For a beam of
range R, the dose ratio may thus be given by
D1
D2
≈ e2
R0−R
λw
(
D1
D2
)
0
, (12)
where R0 and (D1/D2)0 are the beam range and dose
ratio of the ridge filter for reference energy E0/A = 350
MeV. Using an approximate range–energy relation,28 the
beam range was estimated to be 16.3 cm for 290 MeV,
22.2 cm for 350 MeV, 27.6 cm for 400 MeV, and 31.0 cm
for 430 MeV, where we ignored the energy loss mainly
in the variable scatterer. The energy factors for D1/D2
relative to 350 MeV then resulted in e2(R0−R)/λw = 1.59
for 290 MeV, 0.66 for 400 MeV, and 0.50 for 430 MeV.
8. Ridge-filter design data
The ridge filters had been designed to modulate the
carbon-ion range to deliver uniform RBE-weighted dose
over the SOBP region for reference energy E0/A = 350
MeV. Figure 1 shows the depth–dose and depth–RBE
distributions designed for a ridge filter of 6-cm range
modulation, for example. We assumed that the quan-
tity and composition of the secondary particles would
not radically vary with depth up to the tail region, where
primary carbon ions are absent. This leads to approxima-
tions: D2 ≈ Dtail = Dw(dtail) and ǫ2 ≈ ǫtail = ǫw(dtail),
where we chose tail-base depth dtail to be at 3 mm deeper
than the carbon-ion range. The dose and RBE ratios at
the mid-SOBP depth were then estimated by
D1
D2
≈ Dmid −Dtail
Dtail
(13)
and
ǫ1
ǫ2
≈ ǫmid
ǫtail
+
(
ǫmid
ǫtail
− 1
)
Dtail
Dmid −Dtail
, (14)
as shown in Table I. The ǫtail values were reasonably in-
variant among the ridge filters. The apparent Dtail/Dmid
invariance among the ridge filters was due to incidental
cancellation between Dtail, which varied with modulation
M , and Dmid = Dw(dmid), which varied with proximal
shift of mid-SOBP depth dmid = R−M/2.
B. Evaluation of modifying factors
1. Beam experiment
We conducted an experiment with the apparatus iden-
tical to the previous study.5 We tested some of the clini-
cal carbon-ion beams, in which 430-MeV beams were ex-
cluded as they have been only rarely used. The central-
axis doses for fields 10 cm in diameter were measured
with special interest in the mid-to-distal part of the
SOBP, with and without insertion of a 10-cm PE block
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FIG. 1. Ridge-filter design data for extraction energy E/A =
350 MeV and range-modulation width M = 6 cm: (a) rela-
tive dose Dw/Dmid, (b) RBE ǫw, and (c) RBE-weighted dose
ǫwDw/Dmid, as a function of range-subtracted depth in wa-
ter, d− R. Vertical dotted lines indicate the mid-SOBP and
tail-base depths.
in front of a dosimetric water phantom. When the block
was in, the phantom was moved downstream by 10 cm
so that the SOBP would stay in the same position in
the laboratory frame of reference for invariant beam-
divergence effect. For each tested beam, we determined
the mid-SOBP doses and beam-range depths with and
without PE insertion by fitting to the dose distribution
designed for the ridge filter, which led to dose modifying
factor fD, range shift s, and dose attenuation coefficient
κD = (1− fD)/s.
2. Model calculation
While the dose modifying factor could be experimen-
tally measured, it would not represent the clinical PE
effect on RBE-weighted dose. We thus calculated the
dose and clinical-dose modifying factors for every com-
bination of energy and modulation to cover all the clin-
ical carbon-ion beams, according to the formulation de-
scribed in Sec. II A.
TABLE I. Ridge-filter design parameters for reference energy
E0/A = 350 MeV: ridge-filter identifier RF, range modu-
lation M , relative tail-base dose Dtail/Dmid, tail-base RBE
ǫtail, mid-SOBP RBE ǫmid, primary-to-secondary dose ratio
(D1/D2)0, and RBE ratio ǫ1/ǫ2.
RF M
cm
Dtail
Dmid
ǫtail ǫmid
(
D1
D2
)
0
ǫ1
ǫ2
020 2.0 0.221 1.160 2.083 3.52 2.02
025 2.5 0.229 1.156 1.993 3.37 1.94
030 3.0 0.233 1.153 1.917 3.29 1.86
040 4.0 0.239 1.146 1.806 3.18 1.76
050 5.0 0.242 1.138 1.722 3.13 1.68
060 6.0 0.242 1.130 1.660 3.13 1.62
070 7.0 0.241 1.124 1.604 3.15 1.56
080 8.0 0.239 1.118 1.563 3.18 1.52
090 9.0 0.238 1.113 1.521 3.20 1.48
100 10.0 0.235 1.110 1.486 3.26 1.44
110 11.0 0.233 1.108 1.465 3.29 1.42
120 12.0 0.230 1.107 1.431 3.35 1.38
150 15.0 0.224 1.106 1.361 3.46 1.30
C. Treatment planning
1. Model integration
The treatment-planning system uses the pencil-beam
algorithm, with which the clinical-dose distribution is cal-
culated by two-dimensional convolution in the x–y plane
perpendicular to the field-central z axis,
ǫD(x, y, z) =
∫∫
Φx′y′zKx′y′z(x, y, z)dx
′dy′, (15)
where Φx′y′z and Kx′y′z are the in-air fluence and
the convolution kernel on an axis directed to point
(x′, y′, z).29 The in-air fluence distribution was analyti-
cally modeled for the wobbling system.30,31 The kernel,
which is a dose distribution for a virtual pencil beam, is
defined as
Kx′y′z(x, y, z) =
ǫwDw(dx′y′z)
2πσ2x′y′z
e
−
(x−x′)2+(y−y′)2
2σ2
x′y′z , (16)
where ǫwDw is the in-water RBE-weighted dose per in-
air fluence and dx′y′z and σx′y′z are the WE depth and
the rms off-axial spread at point (x′, y′, z).28,32
For this study, we tentatively modified the dose kernel
to reflect the PE effect represented at the mid-SOBP
depth:
Kx′y′z → fǫD(s)Kx′y′z, (17)
where fǫD is the clinical-dose modifying factor as a func-
tion of WE thickness s of the compensator on the kernel
axis.
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2. Case study
To investigate the PE effect on tumor dose, we made
a treatment-planning study. We took two cases of typ-
ical indications for carbon-ion radiotherapy: chordoma
of sacrum and malignant melanoma of nasal cavity and
paranasal sinus. As these tumors tend to be large and
shallow, oblique-incident beams with large range com-
pensation may often be applied.
For the sacrum case, we used real planning CT im-
ages of a prone patient, in which a clinical target volume
had been delineated by a radiation oncologist. In this
simulation study, we did not apply special techniques or
optimization processes normally used in clinical practice
but simply planned one vertical and two opposing hori-
zontal beams to treat the target. Similarly, for the nose-
and-sinus case, we used real planning CT images of a
supine patient, for which we simply planned one vertical
and one horizontal beams. Range compensators were de-
signed to compensate the variation of target exit depth
in the individual fields.
The original and modified dose kernels were used to
calculate plan dose distributions. For each beam in the
original-kernel plan, the clinical dose of 1 Gy (RBE) was
delivered to the center of the target placed at the machine
isocenter. For the beams in the modified-kernel plan,
the same monitor-unit numbers as for the corresponding
beams in the original-kernel plan were set.
III. RESULTS
A. Beam experiment
Figure 2 shows examples of the depth–dose distribu-
tions measured in the experiment. Although the 10-cm
PE should have caused extra carbon-ion attenuation by
4.5%, the dose reduction was within 3% as shown in Table
II. The relative dose reproducibility was typically ±0.2%,
which led to 0.3% for the uncertainty of fD.
B. Model calculation
Figure 3 shows the dose and clinical-dose attenuation
coefficients for PE range shift as a function of range-
modulation width, where we assumed functional continu-
ity for the consistent design among the ridge filters. They
amounted to 0.1%–0.3%/cm for fD and 0.2%–0.4%/cm
for fǫD, which were smaller than the carbon-ion atten-
uation coefficient of 0.45%/cm due to partial compen-
sation by increased secondary particles. Their system-
atic decrease with extraction energy was caused by the
secondary particles increasing with beam range. While
the calculated and measured dose attenuation coefficients
were consistent with each other for 350 MeV and 400
MeV, there was significant disagreement for 290 MeV.
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FIG. 2. Depth–dose distributions for some clinical carbon-
ion beams: with 10-cm PE (×), without PE (©), and design
(dashed line). The vertical dotted lines indicate mid-SOBP
depths in range-subtracted depth (d−R) and the texts indi-
cate extraction energies and range-modulation widths.
TABLE II. Measurement of dose modifying factors for clinical
carbon-ion beams: beam identifier #, energy E/A, ridge-filter
identifier RF, range-modulation width M , range shift s, dose
modifying factor fD, and corresponding figure.
# E/A
MeV
RF M
cm
s
cm
fD Fig.
1 290 020 2.0 9.99 0.974
2 290 040 4.0 9.99 0.979
3 290 060 6.0 10.00 0.982 2(a)
4 350 040 4.0 9.98 0.975
5 350 060 6.0 9.99 0.979 2(b)
6 350 080 8.0 9.99 0.979
7 400 040 4.0 9.99 0.979
8 400 060 6.0 9.99 0.985 2(c)
9 400 080 8.0 9.98 0.983
10 400 120 12.0 9.98 0.985 2(d)
C. Case study
Table III shows the maximum WE thicknesses of the
range compensators. Except for the posterior beam in
the sacrum case, range compensation was large as it had
been expected for oblique-incident beams. Figures 4 and
5 show the plan dose distributions, in which the reduction
of clinical dose was 0.30% at the isocenter in the sacrum
case, 0.75% at the isocenter in the nose-and-sinus case,
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FIG. 3. Dose and clinical-dose attenuation coefficients κD
and κǫD in units of m
−1 or %/cm, as a function of range-
modulation width M : solid lines for κD calculations, dashed
lines for κǫD calculations, and open-circle symbols for κD
measurements.
TABLE III. Maximum water-equivalent thickness tmax of
range compensators designed for clinical cases.
Case Tumor site Beam direction tmax/cm
(a) Sacrum Posterior 6.54
Right 11.48
Left 13.88
(b) Nose and sinus Anterior 9.40
Left 9.04
and mostly within 1% in these targets. In the nose-and-
sinus case, the dose reduction greater than 2% occurred
only in the air that happened to be included in the dose-
calculation volume. Relatively speaking, the dose reduc-
tion was greater in the posterior part of the sacrum target
and in the anterior-left (away from nose) part of the nose-
and-sinus target, which was caused by locally shallower
target depth and hence larger range compensation in the
fields.
IV. DISCUSSION
Disagreement between the measured and calculated
dose attenuation coefficients was found to be about
0.1%/cm for the 290-MeV beams. In the present model,
the relative increase of the secondary-particle dose D2
was equated with the relative decrease of the carbon-ion
FIG. 4. Clinical-dose distribution on the isocenter (+) plane
of trans-axial CT image for the sacrum target (yellowish
region): (a) the modified-kernel plan with 95%–10% (red–
purple) isodose contours and (b) dose reduction from the
original-kernel plan with 1.5%–0.1% (dark red–purple) iso-
dose contours.
dose D1 to correct energy dependence of the dose ratio
D1/D2. Although the inverse relation may be a natural
assumption for the yield of secondary particles, their at-
tenuation and variation of ionization with depth would
disturb the assumed relation for dose. In fact, the wa-
ter thickness from the PE exit to the mid-SOBP depth
is different between 290 MeV and 350 MeV by about 6
cm. Due to reduced attenuation, the secondary-particle
dose for 290 MeV could actually be larger than that ex-
pected from 350 MeV, which would have contributed to
the observed disagreement. Although a similar situation
should apply inversely to the 400-MeV beams, no sig-
nificant disagreement was found there somehow, which
may indicate intrinsic limitations of the two-component
model. It was in principle possible to evaluate those pa-
rameters directly by redoing Monte Carlo simulation for
ridge-filter design in accordance with the two-component
model. However, it would be reasonable to assess the
clinical influence of the PE effect that may possibly be
overestimated by the simple calculation model.
In this study, we assumed invariant secondary-particle
behavior between the mid-SOBP and tail-base depths,
or D2 ≈ Dtail and ǫ2 ≈ ǫtail, to deduce D1/D2 and
ǫ1/ǫ2. In a Monte Carlo study on a pristine 391-MeV
carbon-ion beam in water,33 boron nuclei 10+11B showed
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FIG. 5. Clinical-dose distribution on the isocenter (+) plane
of trans-axial CT image for the nose-and-sinus target (yel-
lowish region): (a) the modified-kernel plan with 105%–10%
(white–purple) isodose contours and (b) dose reduction from
the original-kernel plan with 2.0%–0.1% (white–purple) iso-
dose contours.
notable dose contribution of about 1/4 of the tail-base
dose, which would presumably be further moderated by
range modulation. If we assumeDB = 0.2Dtail+∆DB for
the mid-SOBP boron-nucleus dose with variation ∆DB
among the range modulations and ǫB ≈ ǫ1 ≈ 1.5 ǫ2 for
the boron-nucleus RBE, the dose ratio and the RBE ratio
will vary relatively by
∆D1D2
D1
D2
= −∆D2
D2
≈ −0.2 ∆DB
DB
(18)
and
∆ ǫ1ǫ2
ǫ1
ǫ2
= −∆ǫ2
ǫ2
= − (ǫB − ǫ2)∆DB
D2 +∆DB
≈ −0.1 ∆DB
DB
. (19)
The reduced sensitivity to ∆DB supports the assumption
of invariant secondary-particle behavior for their deriva-
tion. The Monte Carlo study also showed substantial
dose from 10+11C nuclei.33 Because all carbon nuclides
are equivalent in ionization, the neutron-number varia-
tion resulted from neutron removal will only distort the
Bragg peak, which will also be moderated by range mod-
ulation, and thus may be reasonably excluded from con-
sideration.
Range compensators are usually concave-shaped with
WE thickness less than a few centimeters in the middle of
the field and large compensation only applies to the pe-
ripheral part. In other words, reduction of clinical dose in
the core part of a tumor will not be generally large. For
an ideal spherical target, the mean range compensation
will be
∫ 1
0 2r
(
1−
√
1− r2
)
dr = 1/3 of the maximum,
which may also be typical for irregular targets. In an
extreme case in which a beam is applied with range com-
pensation of maximum 20 cm and of expected mean 6.8
cm, the PE effect on clinical dose could go up to 3%.
In reality, however, the maximum range compensation is
typically less than 10 cm and its effect on tumor dose will
be further mitigated with multidirectional beams. It is
therefore reasonable that the PE effect on tumor dose in
the clinical cases resulted in about 1% reduction.
In practical situations, where PE range compensators
are always used, variation of the PE effect among pa-
tients may also be of the order of 1%, which is nor-
mally smaller than dose fluctuation due to limitations of
field uniformity or multiple scatting in heterogeneity.15,34
There are always uncertainties in treatment planning, pa-
tient setup, and beam delivery, which could cause dose
errors typically up to a few percent. In addition, the
present radiobiology model is intrinsically limited in pre-
dicting clinical response in the presence of variability
of radiosensitivity for dose fractionation, cell and tis-
sue types, and individual patient, which could be even
larger. Nevertheless, the PE effect should be corrected
in treatment planning rather than being handled as an
uncertainty, or further the cause should be mitigated by
using another material of better water equivalence such
as polyoxymethylene.5
V. CONCLUSIONS
We have investigated the effect of PE range compen-
sators on tumor dose due to their non water equiv-
alence in nuclear interactions. In the model calcula-
tion, the extra carbon-ion attenuation per range shift of
0.45%/cm caused reduction of 0.2%–0.4%/cm in RBE-
weighted dose for clinical carbon-ion beams. Reduction
in absorbed dose was 0.1%–0.3%/cm, for which the mea-
surements and calculations agreed with each other within
0.1%/cm. The reduction of clinical dose due to PE range
compensation could go up to 3% in extreme cases. In a
realistic treatment-planning study, it was typically within
1% with expected variation of the same order. That
would be marginal as compared to intrinsic uncertainties
originated in treatment planning, patient setup, beam
delivery, and clinical response.
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